The event-free survival rate at 12 months after CAR T-cell treatment in such tumor-derived exosomes prototype patients was only 39%, suggesting that the combination of PD-1 inhibitors or IFN-γ blockers may further enhance the efficacy of CAR T-cell in hematological cancer treatment by interfering with the immunosuppressive function of hyperactivated macrophages [27]. Here, PDCD1 is linked to neoplasm.